The company reported $737 million in U.S. sales for the third quarter and approximately $1.4 billion in worldwide sales. Worldwide sales increased by 5.7 percent over the third quarter of last year. The 1.5 percent decrease in U.S. sales was offset by at 15.3 percent increase in international sales.
Johnson & Johnson’s total expenses due to litigation matters was reported as $654 million during the third quarter, with additional costs of $109 million due to the recall of the DePuy ASR Hip, initiated in the summer of 2010. Johnson & Johnson also reported $214 million in costs associated with acquiring spine device company Synthes.
During the third quarter, the FDA cleared DePuy’s Trumatch personalized solutions system for use with the Sigma fixed-bearing knee system.
Sign up for our FREE Orthopedic E-Weekly for more coverage like this sent to your inbox!
Related Articles on Orthopedic Devices:
OrthoData Names Ric Navarro President and CEO
43 Orthopedic and Spine Devices Receive FDA 510(k) Clearance in October
Zimmer Acquires XtraFix External Fixation System
